Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX06 in Advanced Solid Tumors
NCT03494231Phase 1Terminated
- Sponsor
- Henlix Biotech
- Start
- Mar 2018
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vulinacimab in solid tumor, sponsored by Henlix Biotech. Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 at 1.5 years. Started Mar 2018; status: terminated.
02
Drugs
vulinacimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03494231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03494231.